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ABSTRACT:
FLT3 is a receptor tyrosine kinase that is expressed in CD34+ hematopoietic stem/
progenitor cells (HSPCs) and is important for both normal myeloid and lymphoid 
differentiation. FLT3 expression in Pax5 negative lymphoid precursors coincides with 
a window of multilineage differentiation potential in mice and humans. Recent work 
has shown that FLT3 activating mutations can collaborate with a Nup98-HoxD13 
mutation to induce an aggressive acute leukemia. The leukemic initiating population 
in this model displayed properties of both lymphoid and myeloid precursors, making 
it a useful tool to study the role of FLT3 in lineage plasticity. Through a variety of 
assays, the leukemic initiating population was shown to be restricted to myeloid 
differentiation, suggesting that the B-lineage properties in these cells are due to the 
priming of lymphoid transcription programs in multipotent progenitors rather than a 
true capacity for B-cell maturation. The development of an undifferentiated myeloid 
leukemia in this model, also has implications for the role of FLT3 in the inhibition 
of myeloid differentiation. Here we discuss the insights gained from this model. 
INTRODUCTION 
The commitment of cells to myeloid or lymphoid 
lineage development is considered to be an irreversible 
process, whereby distinct gene expression programs 
are triggered involving epigenetic changes in DNA and 
protein  modification.  However,  there  is  evidence  that 
multipotent progenitor cells prime several different 
lineage programs at low levels in order to respond rapidly 
to external stimuli [1]. Differentiation requires both an 
increase in lineage specific genes and a decrease in gene 
expression associated with alternative lineages. Therefore, 
dysregulation of gene expression by oncogenic mutations 
can lead to lineage conversion or multilineage properties 
in these primitive cells.
Activating mutations of the FLT3 receptor are 
some of the most common alterations in acute myeloid 
leukemia (AML) and have been extensively studied in 
patient samples, cell lines, and model systems [2-5]. We 
recently published a study describing a mouse model of 
cooperation between a knock-in of a FLT3 internal tandem 
duplication (ITD) mutation and a transgenic Nup98-
HoxD13 (NHD13) translocation [6]. While the FLT3/
ITD mutation alone induces a lethal myeloproliferative 
neoplasm (MPN) [7] and the Nup98-HoxD13 translocation 
alone produces a myelodysplastic syndrome (MDS), mice 
bred to express both mutations develop an acute leukemia 
with short latency and 100% penetrance. 
Initially, the leukemia observed in this model 
appeared to express cell surface markers characteristic 
of both primitive myeloid and lymphoid development. 
The induction of a biphenotypic leukemia in this model 
would be surprising given the clinical data documenting 
the  role  of  both  Nup98  translocations  and  FLT3/ITD 
mutations in myeloid disease. The case reports describing 
patients harboring a Nup98-HoxD13 translocation have 
all reported myeloid malignancies; 1 case of therapy 
related acute erythroid leukemia and 3 cases with acute 
myelomonocytic  leukemia  [8-11].  To  date,  no  Nup98 
translocations have been observed in a patient with a 
B-cell malignancy [12]. Similarly, FLT3-ITD mutations 
are largely restricted to subtypes of AML, and are rarely 
reported in cases of acute lymphoblastic leukemia (ALL) 
[2, 13-14]. Finally, the FLT3/ITD-NHD13 model mimics 
the stepwise progression of a pre-leukemic disorder 
characterized by myelodyspasia, to overt leukemia that is 
frequently observed in patients. Approximately, 30% of Oncotarget 2012; 3:  576-580 577 www.impactjournals.com/oncotarget
MDS cases progress to AML, while the progression of 
MDS to ALL is rare [15].
FLT3 in normal and malignant B-cells
Although FLT3 activating mutations appear to be 
primarily restricted to myeloid leukemias in patients, 
wildtype FLT3 is known to be expressed in lymphoid 
precursors and is expressed at low levels in nearly 100% 
of B-cell ALLs, suggesting a role for the receptor in early 
B-cell development [16-18]. Furthermore, subsets of ALL 
associated with specific chromosomal translocations such 
as MLL rearrangements have been shown to express FLT3 
at high levels [19]. Although FLT3 activating mutations 
occur rarely in lymphoid leukemia, they occur at a higher 
frequency  in  subtypes  of  childhood  leukemia  such  as 
hyperdiploid and MLL rearranged ALL [20-21].
In contrast to what is observed in patients, many 
mouse models that result in expression of FLT3 activating 
mutations through retroviral transduction of bone marrow 
or the generation of transgenic or “knock-in” mice have 
reported leukemias that express cell surface markers 
characteristic of biphenotypic or lymphoid development. 
For example, transduction of bone marrow with a 
FLT3 tyrosine kinase domain mutation results in a high 
proportion of lymphoid disease [22]. The combination 
of FLT3/ITD mutations with oncogenic fusions such as 
MLL-SEPT6 and AML1-ETO has also yielded a subset 
of mice with lymphoid disease [23-24]. In addition, a 
retroviral insertional mutagenesis screen in the FLT3/
ITD knock-in background identified a high proportion of 
lymphoid leukemias [25]. 
Regulation of FLT3 in murine B-cell development
One explanation for the development of a myeloid 
disease with early B-lymphoid properties in mice is that 
regulation of FLT3 expression is critical for early B-cell 
maturation.  Gene  knock-out  studies  have  illustrated 
the importance of the balance between FLT3 and Pax5, 
a transcription factor that is critical for B-lineage 
commitment [26-27]. Pax5-/- pre-B cells are susceptible 
to myeloid lineage switching when transduced with C/
EBP α or the GATA family of transcription factors, but 
lose this ability after Pax5 induction [28]. This window 
of multilineage developmental potential is associated 
with FLT3 expression [29]. Holmes et al. have shown that 
Pax5 deficient proB cells express high levels of FLT3, but 
that it is repressed upon ectopic Pax5 expression. Further 
studies in mice have shown that knock-down or over 
expression of FLT3 can have a profound impact on B-cell 
development. FLT3-/- mice have reduced numbers of B-cell 
precursors in the bone marrow, though normal numbers of 
functional B cells are present in the periphery and mice 
lacking FLT3 ligand have decreased numbers of myeloid 
and B-lymphoid progenitors [30-32]. Conversely, forced 
over expression of FLT3 or FLT3 ligand in mouse bone 
marrow results in decreased numbers of B220+CD19+ cells 
[29, 33]. In a more physiologically relevant system, where 
the FLT3/ITD mutation is expressed under the endogenous 
promoter, mice develop a block in differentiation at an 
early pro B-cell stage [34]. Taken together, these studies 
indicate that temporal control of FLT3 expression is 
critical for B-cell maturation. 
Several murine models of hematopoietic 
malignancy have reported leukemias that co-express 
cell surface markers consistent with both myeloid and 
lymphoid cells, typically using B220 as evidence of 
B-cell differentiation. However, B220 appears early in 
hematopoietic differentiation and can also be expressed 
on  many  different  cell  types.  Through  sorting  and 
transplantation of progenitor cell populations from a 
leukemic FLT3/ITD-NHD13 donor mouse, we showed 
that the ability to transplant the disease was restricted 
to a B220+ population with the immunophenotype of a 
multipotent progenitor. However, despite expression of 
B220, the leukemic initiating population was restricted to 
myeloid differentiation in vitro. This population had no 
other B-lymphoid properties. The cells did not display 
B-cell specific transcription factor expression or any other 
cell surface markers consistent with B-cell precursors. 
Although this population had D-to-J rearrangements of 
the IgH locus, they did not show any signs of V-to-DJ 
rearrangements, which are definitive for B- lymphoid cells. 
Single cell analysis of CD19- B-precursor populations in 
the mouse bone marrow have shown that recombination 
activating genes can be detected at low levels in most 
multipotent progenitor cells, a population that retains the 
capacity for myeloid differentiation. Thus, the presence 
of D-to-J rearrangements and surface B220 expression 
may be due to the priming of lymphoid differentiation 
programs at low levels in multipotent progenitors, rather 
than evidence for lymphoid differentiation. 
FLT3 and B220 expression
There is previous evidence of a connection between 
FLT3 signaling and the expansion of hematopoietic stem 
and progenitor cells (HSPCs) expressing B220. One study 
identified a population of CD19-B220+c-KIT+FLT3+ cells 
as early B-lymphoid precursors in juvenile mouse bone 
marrow that is highly dependent on FLT3 expression 
for survival [35-36]. These cells possess the potential 
to produce both lymphoid and myeloid colonies in 
vitro. Other studies observed that FLT3 ligand induces 
the outgrowth of Mac-1+/B220+ mouse bone marrow 
progenitor cells restricted to macrophage differentiation 
that co-express early B-cell associated genes [37]. Pre-
B-cell progenitors with myeloid characteristics have also 
been described when murine cells are transformed with 
several oncogenic receptor tyrosine kinases [38]. Together, Oncotarget 2012; 3:  576-580 578 www.impactjournals.com/oncotarget
these studies suggest that a population of pre-B cells with 
bilineage potential exists within juvenile mice that is 
dependent on FLT3 expression and highly susceptible to 
transformation. 
Recent work has shown that a leukemia initiating 
population with lymphoid characteristics can exist in 
patients with AML, suggesting that the presense of a 
myeloid restricted B220 expressing cell is not a mouse 
specific phenomenon [39]. In this study, CALM/AF10 
positive AML samples were shown to co-express B220 
and CD34, a marker used to define HSPC populations, and 
had detectable clonal immunoglobulin rearrangements. 
Rearrangements of the IgH locus have been observed in a 
significant number of AML cases, suggesting that a larger 
subset of leukemias may also be derived from a progenitor 
population with lymphoid characteristics [40]. 
FLT3 in lineage specification
The presence of a FLT3 activating mutation can also 
affect the lineage restriction of HSPCs. Although FLT3 
mutations are typically categorized by their ability to 
promote survival and proliferation, accumulating data has 
suggested that FLT3/ITD activating mutations can also 
contribute to a block in differentiation [41-42]. Radomska 
et  al.  has  shown  that  constitutive  activation  of  FLT3 
can inhibit CEBPα function through ERK1/2 mediated 
phosphorylation, resulting in a block in differentiation in 
both cell lines and patient samples. Treatment of primary 
blasts with the FLT3 inhibitor CEP701 was able to 
partially reverse this differentiation block, as evidenced 
by increased expression of CEPBα and Pu.1 and enhanced 
granulocytic  differentiation.  This  work  suggests  that 
signaling downstream of the constitutively activated 
receptor may alter the activity of transcription factors that 
are critical for myeloid differentiation. 
The distribution of disease in the FLT3/ITD-NHD13 
model also supports the role of FLT3 mutations in the 
impairment of differentiation. Although the NHD13 alone 
mice all develop a myelodysplastic syndrome, a subset 
of these mice are known to progress to differentiated 
leukemias of both the myeloid and lymphoid lineages [43]. 
These mice develop a variety of differentiated myeloid 
neoplasms including acute megakaryocytic, erythroid, 
and  myelomonocytic  leukemias.  However,  when  this 
mutation  is  combined  with  the  FLT3/ITD  knock-in 
mutation, mice develop strictly minimally differentiated 
myeloid leukemias. This difference in leukemia subtype, 
suggests that the presence of a FLT3/ITD mutation in this 
system results in the transformation of very early myeloid 
precursors that are impaired in maturation. Accordingly, 
HSPCs isolated from the FLT3/ITD-NHD13 mice showed 
an impaired ability of to differentiate in vitro [Greenblatt 
and Small, unpublished data], even compared to the 
NHD13 or FLT3/ITD alone mice [44]. 
In  the  FLT3/ITD-NHD13  mice,  an  early  genetic 
event leading to loss of the wildtype FLT3 allele allows 
us to track cells originating from the leukemic initiating 
population.  Loss  of  heterozygosity  is  never  found  in 
megakaryocytic/erythroid progenitors or CD19+ B-cells 
populations, indicating that the leukemic initiating 
population does not contribute to these lineages. These 
data provide further evidence that FLT3/ITD mutations 
play a role in the regulation of differentiation and lineage 
restriction of the leukemic stem cell. The contribution 
of both mutations to impairment in differentiation may 
also explain why the concomitant expression of a Nup98 
translocation and FLT3/ITD mutation results in a short 
latency to disease in mice and a poor prognosis in patients. 
CONCLUSION 
 This cumulative work suggests that regulation of 
FLT3 expression is critical for both myeloid and lymphoid 
differentiation.  Disturbance  of  FLT3  through  over-
expression or constitutive activation by FLT3 activating 
mutations can result in leukemias with promiscuous 
lineage  properties.  While  these  properties  may  make 
the cells more difficult to treat, they may also provide a 
unique target for treatment since the leukemic initiating 
population may express a cell surface profile distinct from 
normal stem cells. 
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